Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
NEW YORK, December 6, 2023—Julie & Holleman LLP, a nationally recognized shareholder rights law firm, is investigating the proposed $45 per share sale of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) to AbbVie Inc. The firm has already identified potential conflicts of interest related to the merger.
For a free consultation, please fill out the form below or contact partner W. Scott Holleman at (917) 325-3798 or scott@julieholleman.com. There is no cost or obligation to you.
On December 6, 2023, Cerevel announced that it had entered into an agreement for the company to be acquired by AbbVie for $45 per share, or a total of $8.7 billion. The transaction, which is subject to shareholder approval, is expected to close in mid-2024.
Julie & Holleman, whose attorneys have helped secure hundreds of millions of dollars for shareholders, is concerned about potential conflicts, including related to Cerevel’s largest shareholder, Bain Capital.
To learn more about our investigation, please fill out the form below.